Cargando…

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease caused by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotens...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Lanying, He, Yuxian, Zhou, Yusen, Liu, Shuwen, Zheng, Bo-Jian, Jiang, Shibo
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750777/ https://www.ncbi.nlm.nih.gov/pubmed/19198616 http://dx.doi.org/10.1038/nrmicro2090

Ejemplares similares

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine
por: He, Yuxian, et al.
Publicado: (2006)

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model
por: Du, Lanying, et al.
Publicado: (2007)

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine
por: He, Yuxian, et al.
Publicado: (2004)

Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells
por: Du, Lanying, et al.
Publicado: (2009)

Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry
por: He, Yuxian, et al.
Publicado: (2004)

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
por: Zhou, Yusen, et al.
Publicado: (2019)

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity
por: Du, Lanying, et al.
Publicado: (2009)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Vaccines for the prevention against the threat of MERS-CoV
por: Du, Lanying, et al.
Publicado: (2016)

Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection
por: Du, Lanying, et al.
Publicado: (2008)

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients
por: Cao, Zhiliang, et al.
Publicado: (2010)

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2013)

Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity
por: Du, Lanying, et al.
Publicado: (2007)

Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2022)

Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
por: Du, Lanying, et al.
Publicado: (2013)

From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development
por: Ma, Cuiqing, et al.
Publicado: (2020)

SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies
por: Yang, Yang, et al.
Publicado: (2021)

Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2
por: Jiang, Shibo, et al.
Publicado: (2020)

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
por: Ma, Cuiqing, et al.
Publicado: (2014)

Current advancements and potential strategies in the development of MERS-CoV vaccines
por: Zhang, Naru, et al.
Publicado: (2014)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
por: Jiang, Shibo, et al.
Publicado: (2020)

SARS Vaccine Development
por: Jiang, Shibo, et al.
Publicado: (2005)

Receptor-binding domain-based subunit vaccines against MERS-CoV
por: Zhang, Naru, et al.
Publicado: (2015)

Development of SARS vaccines and therapeutics is still needed
por: Jiang, Shibo, et al.
Publicado: (2013)

Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines
por: He, Yuxian, et al.
Publicado: (2005)

Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern
por: Shi, Juan, et al.
Publicado: (2022)

Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines
por: Jiang, Shibo, et al.
Publicado: (2010)

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
por: Xia, Shuai, et al.
Publicado: (2014)

Molecular switches regulating the potency and immune evasiveness of SARS-CoV-2 spike protein
por: Wan, Yushun, et al.
Publicado: (2021)

MERS-CoV spike protein: Targets for vaccines and therapeutics
por: Wang, Qihui, et al.
Publicado: (2016)

Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2)
por: Xiang, Yusen, et al.
Publicado: (2021)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355–359; 2020)
por: Jiang, Shibo, et al.
Publicado: (2020)

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
por: Xia, Shuai, et al.
Publicado: (2020)

Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein
por: Chen, Yuliu, et al.
Publicado: (2022)

High-throughput screening of mutations affecting SARS-CoV-2 spike functions
por: Xia, Shuai, et al.
Publicado: (2023)

Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
por: Hong, Jaewoo, et al.
Publicado: (2021)

A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2013)

Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development
por: Samrat, Subodh Kumar, et al.
Publicado: (2020)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
por: Wang, Qiao, et al.
Publicado: (2023)

Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike
por: Trigueiro-Louro, João, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_05o1otceao6e3lk50oghb2bbvv